Nikolas Naleid

机构：Moffitt Cancer Center, University Hospitals Seidman Cancer Center

发表论文 30 篇 · 总被引 73 次 · h-index 4

代表论文

• Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study (2024 · The Oncologist · 被引 25)
• Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma (2025 · JCO Precision Oncology · 被引 15)
• First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study (2025 · The Oncologist · 被引 6)
• Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials (2025 · Biomedicines · 被引 5)
• Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer (2024 · Cancers · 被引 4)
• Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)